Refractory hodgkin lymphoma

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 463-469

  Von Tresckow, Bastian ^a,b   Engert, Andreas ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Study Group (GHSG)   (Germany)

Author keywords

Allogeneic transplant; Autologous transplant; Brentuximab vedotin; Hodgkin Lymphoma; Refractory

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CHEMOSENSITIVITY; HODGKIN DISEASE; HUMAN; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; AUTOTRANSPLANTATION; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; PREDNISONE; PROCARBAZINE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 84883208274     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/01.cco.0000432524.62475.60     Document Type: Review

References (26)

1. Fisher RI, DeVita VT, Hubbard SP, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90: 761-763.
2. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-230.
3. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive highdose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
4. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-633.
5. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin Lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116-123.
6. Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin Lymphoma. Br J Haematol 2009; 146: 158-163.
7. Kaloyannidis P, Voutiadou G, Baltadakis I, et al. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 451-457. The first large multicentre analysis on the outcome of patients with recurrence of Hodgkin Lymphoma after ASCT.
8. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
9. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol 2012; 30: 907-913. Improvement of PFS in early unfavourable Hodgkin Lymphoma by intensified chemotherapy.
10. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
11. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
12. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 noninferiority trial. Lancet 2012; 379: 1791-1799. Reduced intensity therapy with six cycles of BEACOPP followed by PET-adapted radiotherapy showed excellent PFS and OS results and a low rate of refractory disease in patients with advanced Hodgkin Lymphoma.
13. Borchmann P, Trelle S, Rancea M, et al. First line treatment of advanced stage Hodgkin Lymphoma with six cycles of BEACOPP escalated results in superior overall survival compared to ABVD: results of a network meta-analysis including 10,011 patients. ASH Ann Meeting Abstr 2012; 120: 551.
14. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
15. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189. The phase II trial that led to the approval of brentuximab vedotin in relapsed or refractory Hodgkin Lymphoma.
16. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980-5987.
17. Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy. Haematologica 2012; 97: 1073-1079.
18. Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin Lymphoma. J Clin Oncol 2013; 31: 456-460.
19. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin Lymphoma. Am J Hematol 2010; 85: 320-324.
20. Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291-1296.
21. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
22. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230-238.
23. Marcais A, Porcher R, Robin M, et al. Disease status and stem cell source impact on the results of reduced intensity conditioning transplant for Hodgkin Lymphoma: a retrospective study from the French Society of Bone Marrow Graft Transplantation and Cellular Therapy. Haematologica 2013. [Epub ahead of print]
24. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study: a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310-317. The largest prospective trial that has so far been performed with RIC-allo in Hodgkin Lymphoma.
25. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin Lymphoma. Blood 2012; 119: 6379-6381. Brentuximab vedotin as a bridge to allogeneic transplant in patients with refractory disease.
26. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013; 98: 611-614.